High-dose-rate intraluminal brachytherapy for bile duct carcinoma after surgery.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1712977.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Five patients with recurrent or residual bile duct carcinoma after surgery were treated with high-dose-rate intraluminal brachytherapy (HDRIBT) using a remote afterloader. External radiotherapy was also given in three cases. HDRIBT is considered to be an effective mode of radiotherapy for residual or recurrent bile duct tumors.
Medical subject headings
- Bile Duct Neoplasms
- Brachytherapy
- Radiotherapy, High-Energy